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Dendritic cells (DC), as the most potent antigen-presenting cells
known, are of increasing interest in tumour immunotherapy
(Austyn, 1998). There is evidence that gene therapy, using both
prodrug activation and cytokines, acts by stimulating immune
responses to dying tumour cells (Melcher et al, 1998) and that DC
may be important in initiating these responses, perhaps by the
uptake of apoptotic tumour cells and the presentation of tumour
antigens (Rubartelli et al, 1997b; Albert et al, 1998). DC generated
in vitro from monocytes using granulocyte–macrophage colony-
stimulating factor (GM-CSF) and interleukin-4 (IL-4) are being
used widely in clinical trials to assess directly DC efficacy in
inducing immune responses against tumours (Bender et al, 1996;
Nestle et al, 1998). Combining chemotherapy and immunotherapy
is a logical extension of current trials and is already in use for
some tumours, such as renal carcinoma and melanoma. The
chemosensitivity of DC is unknown but is important to the rational
development of combined modality regimens in which
chemotherapy agents do not detract from the immune response
against the tumour. In this paper we used the MTS (Owen’s
reagent) assay to study the effects of several different classes of
cytotoxic drugs on DC survival and demonstrated a marked differ-
ence in sensitivity both to different classes of chemotherapy agents
and between individuals.
MATERIALS AND METHODS
Generation of cultured DC
Commercial buffy coats were obtained from Bristol Blood
Transfusion Service (Bristol, UK) and were all from normal blood
donors. Peripheral blood mononuclear cells were isolated using
Lymphoprep (Nycomed, Norway) as per manufacturer’s instruc-
tions. Human monocyte-derived DC were generated as described
by Bender et al (1996) up to day 6 to obtain immature DC and
were not matured further. Culture medium was RPMl-1640 (Life
Technologies, Paisley, UK) supplemented with 1% autologous
plasma, 50 ng ml–1 GM-CSF (Novartis, Camberley, UK) and 50 ng
ml–1 IL-4 (Peprotech, Boston, MA, USA). Contaminating lympho-
cytes were removed with anti-CD3 and anti-CD19 antibodies
(Dako, Glostrup, Denmark) followed by M-450 Dynabeads coated
with sheep anti-mouse antibody (Dynal, Oslo, Norway) as per
manufacturer’s instructions. The resultant preparation routinely
contained > 90% DC as defined by high expression of HLA-DR
and CD86 and lack of expression of CD3, CD19 and CD14 by
flow cytometry (data not shown).
MTS assay
Purified DC were plated in flat-bottomed 96-well plates at 105,
5 ´ 104, 104, 5 ´ 103 and 103 DC per well in triplicate to generate
standard curves. To assess DC survival after chemotherapy, 5 ´
104 DC were plated per well in triplicate for each concentration of
cytotoxic drug. Doxorubicin (Farmitalia, St Albans, UK), an
anthracycline and topoisomerase II inhibitor which also generates
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free radicals, was used at 0.1, 1, 5, 10 and 50 mM. Etoposide
(Bristol-Myers Squibb, Hounslow, UK), a podophyllotoxin and
topoisomerase II inhibitor without free radical generation, was
used at 0.2, 2, 20, 100 and 200 mM. 5-Fluorouracil (5-FU; Roche,
Welwyn Garden, UK), an antimetabolite, was used at 0.7, 7,
77, 770 and 7700 mM (corresponding to 0.1, 1, 10, 100 and
1000 mg ml–1). Vinblastine (Eli Lilly, Basingstoke, UK), a vinca
alkaloid, was used (at 0.025, 0.25, 2.5, 25 and 250 mM). Drugs
were diluted in complete medium immediately before addition to
DC cultures. DC were incubated with drugs for 2 h at 37°C, 5%
carbon dioxide, washed twice with fresh medium and incubated
for a further 4 days before MTS assay (Promega, Madison, WI,
USA). Results for standard curves are expressed as the mean
optical density (OD) of triplicate wells ± standard deviation (s.d.)
to illustrate differences in colorimetric change seen between
donors, or as percentage survival of DC ± s.d. to obtain the IC50
which is the dose of drug causing 50% reduction in DC survival.
To validate the MTS assay against conventional cell counting, one
set of experiments for each chemotherapy agent included a parallel
96-well plate, which was assessed by counting five fields of view
at 3200 magnification per well following trypan blue. All cell
counts were carried out by the same individual who was blinded to
the MTS assay results for that experiment. The curves were gener-
ated by non-linear regression fit using the Prism program
(GraphPad Software, San Diego, CA, USA). Each cytotoxic drug
was assayed in duplicate with three different donors.
Allogeneic mixed lymphocyte reaction
DC were exposed to chemotherapy agents as described above.
Varying numbers of DC were then cultured with a constant
number of 105 nylon wool purified allogeneic T-cells (highest
concentration 104 DC per well with successive halving dilutions)
for 5 days (Romani et al, 1996). T-cell proliferation was measured
by [3H]thymidine incorporation (0.5 mCi well–1) and expressed as
the mean cpm of triplicate wells ± s.d.
Assays for P-glycoprotein expression
DC were stained for P-glycoprotein (P-gp) expression using
monoclonal antibody UIC-2 (Immunotech, Marseille, France) and
rabbit anti-mouse F(ab)2– fluorescein isothiocyanate (FITC; Dako,
Glostrup, Denmark) for flow cytometry as per manufacturers’
instructions. For the functional assay, MTS plates were set up as
above using a donor who had previously exhibited high resistance
to vinblastine. One set of DC were treated with vinblastine as
previously, and a parallel set was treated with vinblastine and vera-
pamil (20 mM, Abbott Laboratories, Maidenhead, UK) simultane-
ously. The breast cancer cell line MC7F-Adr, which expresses
high levels of P-gp, was used as the positive control for assays.
RESULTS
Human dendritic cells generated reproducible results
in the MTS assay
The MTS assay provided a reliable technique to count DC. Figure
1 demonstrates three points. First, DC were capable of generating
significant colorimetric change in the MTS assay and the OD490
correlated with numbers of DC present over a wide range (103 to
greater than 105). Lymphocytes did not generate a significant
colorimetric change and, even though we routinely purified our
DC populations, parallel experiments with non-purified DC
showed that contaminating lymphocytes did not contribute signifi-
cantly to the colourimetric change (data not shown). Second, DC
gave reproducible results. Standard curves from separate donors
were different but were reproducible on different DC preparations
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Figure 1 Standard curves generated by DC in the MTS assay from two
different donors in duplicate experiments at different times. Donor A,
experiment 1 (n n) and experiment 2 (n). Donor B, experiment 1 (s) and
experiment 2 (s s). Bars, s.d.
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Figure 2 (A) Sensitivity of DC from donor C to doxorubicin as assessed by
the MTS assay (n) or by cell counting (x). The IC50 given by the MTS assay
is 207 nM and by cell counting is 262 nM. Bars, s.d. (B) Sensitivity of DC from
donor C to etoposide as assessed by the MTS assay (n) or by cell counting
(x). The IC50 given by the MTS assay is 120 mM and by cell counting is 102
mM. Bars, s.d.1282 D Chao et al
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assayed at different times. Third, the standard curves showed that
an apparent plateau value of colorimetric change occurred at
around 5 ´ 104 cells well–1, and therefore this cell concentration
was selected for all subsequent survival experiments with
chemotherapy agents.
MTS assay results correlated with conventional cell
counting
It was important to confirm that the MTS assay gave comparable
results to conventional cell counting and to exclude the possibility
that the chemotherapy agents interfered in any way with the MTS
assay to give false results. Figure 2 shows the results of two
parallel plates of DC from one donor treated with doxorubicin or
etoposide and read by either the MTS assay or conventional cell
counting. The IC50 for doxorubicin and etoposide for this donor are
highly similar whether derived by the MTS assay or conventional
cell counting.
DC were sensitive to doxorubicin and vinblastine but
resistant to etoposide and 5-FU
Figure 3A shows that DC were sensitive to doxorubicin and that
DC from different individuals showed varying sensitivities with
IC50 of 244 nM (s), 253 nM (n n) and 1100 nM (n). In contrast, DC
from the same three donors showed relative resistance to the effect
of etoposide (Figure 3B) with no toxicity evident until 50 mM for
all donors. We also tested longer exposures to etoposide, up to
24 h, with no observed differences (data not shown). The greatest
variation in sensitivity was seen for vinblastine (Figure 3C) with
IC50 of 0.15 mM (s), 1 mM (n n) and 17.25 mM (n), which is three
log orders difference in sensitivity for these three donors. DC were
resistant to 5-FU (Figure 3D), with the IC50 not being reached for
any donor and there was no significant toxicity up to 770 mM.
DC function in the allogeneic MLR correlated with the
MTS assay
DC from donor D were relatively insensitive to etoposide at the
highest concentration of 200 mM and this was reflected in the
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Figure 3 (A) Sensitivity of DC to doxorubicin in the MTS assay. Donor D (n), donor E (n n) and donor F (s). Bars, s.d. (B) Sensitivity of DC to etoposide in the
MTS assay. Same three donors as shown in A. Donor D (n), donor E (n n) and donor F (s). Bars, s.d. (C) Sensitivity of DC to vinblastine in the MTS assay.
Same three donors as shown in A. Donor D (n), donor E (n n) and donor F (s). Bars, s.d. (D) Sensitivity of DC to 5-fluorouracil in the MTS assay. Donor G (s),
donor H (n n) and donor K (n). Bars, s.d.Dendritic cells and chemotherapy 1283
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allogeneic MLR (Figure 4A) with normal stimulatory activity up
to 200 mM. In contrast, DC from donor F was sensitive to etopo-
side at the highest concentration of 200 mM, and this correlated
with significantly reduced activity at 200 mM (Figure 4B). Similar
data were obtained following exposure to the other drugs (data not
shown).
Differential sensitivity to chemotherapy agents was not
due to expression of P-gp
There was no expression of P-gp on DC by flow cytometry (data
not shown). In case P-gp was expressed at levels below the
threshold of detection by flow cytometry, we used a functional
inhibition assay using verapamil at a concentration previously
shown to be inhibitory for P-gp (Randolph et al, 1998). There
was no increase in the chemosensitivity to vinblastine, and the
similarly treated standards showed that the verapamil had not
affected the MTS assay (data not shown).
DISCUSSION
The MTS assay depends upon mitochondrial function and can be
used as a measure of cell viability. It is routinely used to assess the
chemosensitivity of tumour cell lines by inhibition of proliferation
(Cory et al, 1991). However, monocyte-derived DC are non-
proliferating cells and we adapted the MTS assay to measure
survival of DC after exposure to chemotherapy agents. We have
shown that the MTS assay gives reproducible results which are
consistent with DC survival assessed by conventional cell
counting with trypan blue exclusion. The major advantage of the
MTS assay is that it is automated and therefore much simpler than
manual cell counting. We chose four different cytotoxic drugs
which are representative of chemotherapy agents commonly used
for the treatment of cancers in which immunotherapy is also being
investigated, and at doses which pharmacokinetic studies suggest
are achievable in vivo.
The results for doxorubicin and etoposide are considered
together because the same three donors were used and both drugs
act on topoisomerase II. Etoposide is more specific and only
inhibits proliferating cells, which may account for its low toxicity
for non-proliferating DC. In contrast, doxorubicin has multiple
sites of action including free radical generation. A bolus of
doxorubicin, 75 mg m–2, gave a peak plasma concentration of 5 mM
falling off to 0.1 mM by 1 h, followed by a long half-life of 30 h
(Greene et al, 1983); these concentrations were toxic to DC in this
study. A bolus of etoposide, 125 mg m–2, gave a peak plasma
concentration of 40 mM, with clearance by 24 h (Henwood and
Brogden, 1990). We have shown that there is no toxicity of this
drug in the MTS assay up to 50 mM for 2 and 24 h.
Pharmacokinetic studies for vinblastine after a bolus of 10 mg
showed a peak plasma concentration of 0.25 mM falling to 1 nM
after 2 h (Nelson et al, 1980). The variation in sensitivity for
vinblastine was so large that at these plasma concentrations DC
from some individuals may be sensitive, whereas others may be
completely resistant. Vinblastine inhibits the polymerization of
tubulin and the formation of the mitotic spindle. Thus resistance
may be related to non-proliferation of DC, but the variable toxicity
suggests that there may be other factors.
The same three donors (donors D, E and F) showed variable
resistance to doxorubicin and vinblastine but all showed relative
resistance to etoposide. This pattern of chemoresistance has simi-
larities to the classic multidrug resistance conferred by P-gp, the
product of the MDR-1 gene. P-gp has recently been identified on
Langerhans cells and may have a role in cell migration (Randolph
et al, 1998). We were unable to demonstrate the expression of P-gp
on monocyte-derived DC by flow cytometry or to show a func-
tional effect on vinblastine sensitivity by verapamil inhibition. The
multidrug resistance-associated protein (MRP) is unlikely to be
involved because MRP overexpression is associated with resis-
tance to etoposide but not to vinblastine (Berger et al, 1997).
Pharmacokinetic studies for 5-FU after a bolus of 900 mg m–2
showed peak plasma concentration of 300 mM with undetectable
levels by 2 h (Fraile et al, 1980). In the MTS assay no toxicity is
seen up to 770 mM for 2 h, suggesting that bolus administration of
5-FU will not be toxic to DC. 5-FU is incorporated into both RNA
and DNA and the basis of DC resistance is not clear.
It is possible that chemotherapy agents may alter DC function
without affecting viability. To address this issue we assessed DC
stimulatory function with the allogeneic MLR which is a standard
assay. We acknowledge that the MLR does not assess all aspects of
DC function, but it is functionally relevant as it correlates well
with other parameters of DC stimulatory function such as expres-
sion of costimulatory molecules (Bender et al, 1996), and
currently many mechanisms of DC function are poorly understood
and so cannot be assessed. These limitations add to the difficulties
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Figure 4 (A) Function of DC from donor D in allogeneic MLR after
treatment with etoposide. Untreated DC (X), DC treated with 200 nM
etoposide (n n) and DC treated with 200 mM etoposide (n). Bars, s.d.
(B) Function of DC from Donor F in allogeneic MLR after treatment with
etoposide. Untreated DC (X), DC treated with 200 nM etoposide (n n) and DC
treated with 200 mM etoposide (n). Bars, s.d.1284 D Chao et al
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of extrapolating from the in vitro model to the in vivo situation, but
the data presented here at least allows us to formulate clinical
models which might be tested. Thus the low toxicity of etoposide
and 5-FU to DC at clinically relevant plasma levels suggest their
use in combined modality studies. 5-FU is of interest because it is
already in use in combined modality treatment with IL-2 and
interferon-a in renal carcinoma, and 5-FU can be given as a
prodrug, 5-fluorocytosine, in gene therapy (Mullen et al, 1992).
Recent studies suggest that DC present antigens acquired by
uptake of apoptotic cells (Rubartelli et al, 1997a; Albert et al,
1998) and we are investigating whether 5-FU and etoposide might
enhance DC immunotherapy through tumour apoptosis without
causing toxicity to DC.
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